Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 19/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | PDE2A | O00408 | 1/20 | 0.72 |
| ▸ | RGS12 | O14924 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.72 |
| ▸ | PDE6D | O43924 | 1/20 | 0.72 |
| ▸ | PDE8A | O60658 | 1/20 | 0.72 |
| ▸ | GMNN | O75496 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | PDE5A | O76074 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mopidamol SCHEMBL30179377 | 1.00 | SLC29A1 (0.72) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Mopidamol SCHEMBL29352335 | 1.00 | SLC29A1 (0.72) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Mopidamol SCHEMBL28140838 | 0.89 | SLC29A1 (0.58) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Mopidamol SCHEMBL28300223 | 0.85 | SLC29A1 (0.53) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL3980595 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL29381078 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL30416820 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL16119 | 0.85 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL2456302 | 0.84 | SLC29A1 (0.49) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL5055200 | 0.83 | SLC29A1 (0.52) | SLC29A1ADORA3KDM4EMEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 19510 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| EP-3277381-B1 | NITROBENZYL DERIVATIVES OF ANTI-CANCER AGENTS | OBI PHARMA INC (TW) | 2026-01-07 | — | — | EP | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-0169465-B1 | MIXTURE OF PYRIMIDO-PYRIMIDINES AND O-ACETYL-SALICYLIC ACID, OR THEIR PHARMACOLOGICALLY ACCEPTABLE SALTS, AND ITS USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-28 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| EP-0306846-A2 | Synergistic combination comprising a phosphodiesterase inhibitor and a thromboxane-A2 antagonist, and its use or preparation | Dr. Karl Thomae GmbH (DE) | 1989-03-15 | — | — | EP | claimed |
| EP-0257344-A1 | Medicaments containing dipyridamol or mopidamol and O-acetylsalicylic acid, or its physiologically compatible salts, process for their manufacture and their use in combating the formation of thrombus | Dr. Karl Thomae GmbH (DE) | 1988-03-02 | — | — | EP | claimed |
| US-4694024-A | ANTICOAGULANT MIXTURE | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-15 | — | — | US | claimed |
| US-4650664-A | INCREASED BIOAVAILABILITY | DR. KARL THOMAE GMBH (DE) | 1987-03-17 | — | — | US | claimed |
| EP-0108898-B1 | ORAL GALENICAL FORMS OF MOPIDAMOL | Dr. Karl Thomae GmbH (DE) | 1986-08-20 | — | — | EP | claimed |
| US-4596705-A | Mopidamol or salt thereof and acid substance in ratio 1:1 | DR. KARL THOMAE GMBH (DE) | 1986-06-24 | — | — | US | claimed |
| EP-0169465-A2 | Mixture of pyrimido-pyrimidines and O-acetyl-salicylic acid, or their pharmacologically acceptable salts, and its use | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-01-29 | — | — | EP | claimed |
| EP-0108898-A1 | Oral galenical forms of mopidamol | Dr. Karl Thomae GmbH (DE) | 1984-05-23 | — | — | EP | claimed |